The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer

BACKGROUND: Myeloid derived suppressor cells (MDSCs) present a significant obstacle to cancer immunotherapy because they dampen anti-tumor cytotoxic T cell responses. Previous groups, including our own, have reported on the myelo-depletive effects of certain chemotherapy agents. We have shown previo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Immunol
Autors principals: Luker, Andrea J., Graham, Laura J., Smith, Timothy M., Camarena, Carmen, Zellner, Matt P., Gilmer, Jamie-Jean S., Damle, Sheela R., Conrad, Daniel H., Bear, Harry D., Martin, Rebecca K.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045411/
https://ncbi.nlm.nih.gov/pubmed/32106810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12865-020-0337-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars